Cerulean to Host Third Quarter 2016 Conference Call on November 3
October 27 2016 - 7:00AM
Business Wire
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company
developing nanoparticle-drug conjugates (NDCs), today announced it
will provide an update on corporate activities for the third
quarter 2016 on November 3.
Management will conduct a conference call at 4:30 p.m. ET that
day to provide a business update and review the Company’s third
quarter financial results. This call can be accessed by dialing
(844) 831-3031 or (443) 637-1284 prior to the start of the call and
referencing conference ID 7618037.
The conference call also will be webcast live over
the Internet and can be accessed on the "Investors"
section of the Cerulean website, www.ceruleanrx.com. The
webcast will be archived on the Company's website for two
weeks.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people
living with cancer. We apply our Dynamic Tumor Targeting™ Platform
to create a portfolio of nanoparticle-drug conjugates (NDCs)
designed to selectively attack tumor cells, reduce toxicity by
sparing the body's normal cells, and enable therapeutic
combinations. Our first platform-generated NDC clinical candidate,
CRLX101, is in clinical trials in combination with other cancer
treatments, all of which aim to unlock the power of combination
therapy. Our second platform-generated NDC clinical candidate,
CRLX301, is in a Phase 1/2a clinical trial. For more information,
please visit http://www.ceruleanrx.com/.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161027005788/en/
Cerulean Pharma Inc.Nicole P. Jones, 781-209-6385Director,
Investor Relations andCorporate
Communicationsnjones@ceruleanrx.comorArgot PartnersSusan Kim,
212-600-1902Investor Relationssusan@argotpartners.com
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024